How much revenue does Item 9 Labs make?

Item 9 Labs reported $21.76 million in revenue for fiscal year 2022, down 0.8% from $21.94 million in fiscal year 2021. In Q3 2023 revenue was $5.02 million.

What is Item 9 Labs's largest business segment?

Corporate and Other, with $21.76 million or 50% of segment revenue in fiscal year 2022. Next: Cultivation Segment (49%) and Franchising Segment (1%).

What companies are similar to Item 9 Labs?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Industry Source Consulting, Inc. (INSO), GeneLink, Inc. (GNLKQ), VIA Pharmaceuticals, Inc. (VIAP), Valeo Pharma Inc. (VPHIF).

Item 9 Labs Corp. (INLB) Stock

About Item 9 Labs Corp.

Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. It operates through Cultivation, Franchising, and Corporate segments. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies thro...

At a glance

Item 9 Labs reported revenue of $21.76 million for fiscal year 2022, down 0.8% from fiscal year 2021, and net income of -$31.14 million. In Q3 2023 (the quarter ended June 30, 2023) revenue was $5.02 million, up 1.8% from a year before. Its largest business segment, Corporate and Other, brought in 50% of segment revenue in fiscal year 2022.

Figures from company filings; latest fiscal year ended September 30, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.